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the
MaBACKGROUND There is limited information on the incidence and prognostic impact of new-onset atrial ﬁbrillation
(NOAF) following percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) for left
main coronary artery disease (LMCAD).
OBJECTIVES This study sought to determine the incidence of NOAF following PCI and CABG for LMCAD and its effect
on 3-year cardiovascular outcomes.
METHODS In the EXCEL (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main
Revascularization) trial, 1,905 patients with LMCAD and low or intermediate SYNTAX scores were randomized to PCI
with everolimus-eluting stents versus CABG. Outcomes were analyzed according to the development of NOAF
during the initial hospitalization following revascularization.
RESULTS Among 1,812 patients without atrial ﬁbrillation on presentation, NOAF developed at a mean of 2.7  2.5 days
after revascularization in 162 patients (8.9%), including 161 of 893 (18.0%) CABG-treated patients and 1 of 919 (0.1%)
PCI-treated patients (p < 0.0001). Older age, greater body mass index, and reduced left ventricular ejection fraction
were independent predictors of NOAF in patients undergoing CABG. Patients with versus without NOAF had a
signiﬁcantly longer duration of hospitalization, were more likely to be discharged on anticoagulant therapy, and had an
increased 30-day rate of Thrombolysis In Myocardial Infarction major or minor bleeding (14.2% vs. 5.5%; p < 0.0001).
By multivariable analysis, NOAF after CABG was an independent predictor of 3-year stroke (6.6% vs. 2.4%;
adjusted hazard ratio [HR]: 4.19; 95% conﬁdence interval [CI]: 1.74 to 10.11; p ¼ 0.001), death (11.4% vs. 4.3%;
adjusted HR: 3.02; 95% CI: 1.60 to 5.70; p ¼ 0.0006), and the primary composite endpoint of death, MI, or stroke
(22.6% vs. 12.8%; adjusted HR: 2.13; 95% CI: 1.39 to 3.25; p ¼ 0.0004).
CONCLUSIONS In patients with LMCAD undergoing revascularization in the EXCEL trial, NOAF was common after CABG
but extremely rare after PCI. The development of NOAF was strongly associated with subsequent death and stroke in
CABG-treated patients. Further studies are warranted to determine whether prophylactic strategies to prevent or treat
atrial ﬁbrillation may improve prognosis in patients with LMCAD who are undergoing CABG. (Evaluation of XIENCE
Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization [EXCEL]; NCT01205776)
(J Am Coll Cardiol 2018;71:739–48) © 2018 by the American College of Cardiology Foundation.alties from Abbott Vascular for sale of the MitraClip. All other authors have reported that they have no relationships relevant to
contents of this paper to disclose. Atul Verma, MD, served as Guest Editor for this paper.
nuscript received November 14, 2017; revised manuscript received November 29, 2017, accepted December 8, 2017.
AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation or ﬂutter
BMI = body mass index
CABG = coronary artery bypass
grafting
CI = conﬁdence interval
HR = hazard ratio
LMCAD = left main coronary
artery disease
LVEF = left ventricular
ejection fraction
MI = myocardial infarction
NOAF = new-onset atrial
ﬁbrillation or ﬂutter
PCI = percutaneous coronary
intervention
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741R ecent randomized trials have suggested thatpercutaneous coronary intervention (PCI)with contemporary drug-eluting stents is an
acceptable alternative to coronary artery bypass graft
surgery (CABG) for selected patients with left main
coronary artery disease (LMCAD) (1,2). As such, iden-
tiﬁcation of pre-procedural and post-procedural fac-
tors that affect outcomes after both
revascularization modalities may affect the choice be-
tween PCI and CABG. New-onset atrial ﬁbrillation
(NOAF) is a common post-operative complication of
CABG, and in earlier studies (mostly in patients with
multivessel disease), NOAF was associated with pro-
longed hospitalization, increased rates of adverse
events, and greater health care costs (3,4). A recent
analysis from the MAIN-COMPARE registry (Revascu-
larization for Unprotected Left MAIN Coronary Artery
Stenosis: COMparison of Percutaneous Coronary
Angioplasty versus Surgical REvascularization From
Multi-Center Registry) in Asia reported that pre-
operative atrial ﬁbrillation (AF) was a predictor of
long-term morbidity and mortality after CABG in pa-
tients with LMCAD (5); however, the incidence and
prognostic impact of NOAF following contemporary
PCI and CABG in patients with LMCAD in sinus
rhythm are largely unknown. In the present study,
we sought to determine the incidence, predictors,
and outcomes of NOAF in patients with LMCAD who
underwent percutaneous or surgical revasculariza-
tion in the randomized EXCEL trial (Evaluation of
XIENCE Versus Coronary Artery Bypass Surgery for
Effectiveness of Left Main Revascularization).SEE PAGE 749METHODS
STUDY DESIGN AND ENDPOINTS. The design of the
EXCEL trial has been reported previously (1,6). In
brief, EXCEL was an international, multicenter, ran-
domized trial that compared everolimus-eluting
stents with CABG in patients with LMCAD and low
or intermediate SYNTAX (Synergy Between Percuta-
neous Coronary Intervention With Taxus and Cardiac
Surgery) scores (#32) in whom equipoise for revas-
cularization with both techniques was present after
heart team review. Randomization was performed
with the use of an interactive voice-based or Internet-
based system in block sizes of 16, 24, or 32, with
stratiﬁcation according to diabetes (present vs.
absent), SYNTAX score (#22 vs. $23), and study
center. The goal of PCI was complete revasculariza-
tion of all ischemic territories with ﬂuoropolymer-
based cobalt-chromium everolimus-eluting stents(Xience, Abbott Vascular, Santa Clara, Cali-
fornia). CABG was performed with or without
cardiopulmonary bypass according to the
discretion of the operator, with the goal of
complete anatomic revascularization of all
vessels $1.5 mm in diameter with $50%
diameter stenosis; the use of multiple arterial
grafts was strongly recommended. Beta-
blockers (or amiodarone for patients with
contraindications to beta-blocker use) were
recommended for pre-operative prophylaxis
of post-operative AF in the surgical arm of the
trial. All CABG-treated patients were to
receive beta-blockers post-procedure unless
contraindicated. Amiodarone use for 5 days
post-CABG was also allowed in all patients for
rhythm control according to the local stan-
dard of care. Use of other medications in the
PCI and CABG arms of the trial has been described
previously (1,6).
The primary endpoint was a composite of death
from any cause, stroke, or myocardial infarction (MI)
at 3 years. Major powered secondary endpoints
included the primary composite endpoint at 30 days
and the composite of death, stroke, MI, or ischemia-
driven revascularization at 3 years. Additional
secondary endpoints included the components of the
primary and secondary endpoints at 30 days and
3 years, stent thrombosis and symptomatic graft
stenosis or occlusion at 30 days and 3 years, and
periprocedural major adverse events occurring within
30 days, all as previously deﬁned (1,6). NOAF was
deﬁned as the occurrence of any episode of AF or
ﬂutter (collectively termed AF for this analysis)
following the index procedure through the time of
discharge that lasted at least 30 s and was captured on
a standard 12-lead electrocardiogram or cardiac
telemetry, or that required medical treatment.
The investigation was approved by the Institutional
Review Board or Ethics Committee at each partici-
pating center, and all patients signedwritten informed
consent forms. Major endpoints were adjudicated by
an independent clinical events committee (Cardio-
vascular Research Foundation, New York, New York).
Angiographic analyses were performed at an angio-
graphic core laboratory (Cardiovascular Research
Foundation). Follow-up is currently complete for all
patients through 3 years. Median follow-up for clinical
outcomes was 3 years.
STATISTICAL METHODS. For the purpose of this
study, arrhythmic events during the hospitalization
following the index CABG or PCI procedure were
analyzed. All analyses were performed in the
TABLE 1 Baseline Characteristics According to the Development of In-Hospital
New-Onset Atrial Fibrillation
NOAF
(n ¼ 162)
No NOAF
(n ¼ 1,650) p Value
Age, yrs 69.0  8.1 65.4  9.6 <0.0001
Female 33/162 (20.4) 383/1,650 (23.2) 0.41
Hyperlipidemia 122/162 (75.3) 1,143/1,647 (69.4) 0.12
Hypertension 119/162 (73.5) 1,211/1,650 (73.4) 0.99
Prior stroke or transient ischemic attack 9/162 (5.6) 102/1,649 (6.2) 0.75
Congestive heart failure 6/162 (3.7) 107/1,645 (6.5) 0.16
Diabetes mellitus, medically treated 38/162 (23.5) 441/1,650 (26.7) 0.37
Chronic obstructive pulmonary disease 18/162 (11.1) 117/1,647 (7.1) 0.06
History of anemia 23/161 (14.3) 152/1,646 (9.2) 0.04
History of carotid artery disease 9/160 (5.6) 140/1,644 (8.5) 0.20
Peripheral vascular disease 20/160 (12.5) 157/1,646 (9.5) 0.23
Critical pre-operative state 4/162 (2.5) 24/1,649 (1.5) 0.31
Valve disease (moderate or less)
Aortic stenosis 5/150 (3.3) 36/1,536 (2.3) 0.40
Mitral stenosis 2/149 (1.3) 9/1,529 (0.6) 0.25
Aortic regurgitation 21/150 (14.0) 162/1,527 (10.6) 0.20
Mitral regurgitation 53/150 (35.3) 435/1,531 (28.4) 0.07
Tricuspid regurgitation 37/148 (25.0) 383/1,517 (25.2) 0.95
Prior percutaneous coronary intervention 34/162 (21.0) 272/1,648 (16.5) 0.15
Previous cardiac surgery 0/162 (0.0) 8/1,650 (0.5) 1.00
Prior myocardial infarction 36/161 (22.4) 276/1,637 (16.9) 0.08
Clinical presentation
Recent MI (within 7 days) 29/162 (17.9) 242/1,643 (14.7) 0.28
ST-segment elevation MI 2/162 (1.2) 24/1,637 (1.5) 1.00
Non-ST-segment elevation MI 27/162 (16.7) 210/1,637 (12.8) 0.17
Unstable angina 35/162 (21.6) 411/1,643 (25.0) 0.34
Body mass index, kg/m2 29.3  5.4 28.5  4.9 0.14
Left ventricular ejection fraction, % 56.1  9.1 57.4  9.2 0.05
SYNTAX score (core laboratory assessed) 26.5  9.6 26.6  9.4 0.90
Baseline laboratory values
Creatinine clearance, ml/min 87.1  32.8 90.1  32.2 0.16
Hemoglobin, g/dl 13.5  1.6 13.6  1.6 0.74
Brain natriuretic peptide, units 241.6  427.3 224.7  557.2 0.04
CHADS2 score 1.7  1.3 1.6  1.3 0.45
CHA2DS2-VASc score 3.3  1.4 3.2  1.4 0.29
Values are mean  SD or n/N (%).
CHADS2 ¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, and stroke, transient
ischemic attack, or thromboembolism; CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75 years,
diabetes mellitus, and stroke, transient ischemic attack, or thromboembolism; vascular disease, age 65 to
74 years, and female sex; MI ¼ myocardial infarction; NOAF ¼ new-onset atrial ﬁbrillation or ﬂutter;
SYNTAX ¼ Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery.
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742as-treated population, excluding patients with
in-hospital AF before the index procedure and those
who did not undergo revascularization procedures.
Continuous variables are reported as mean  standard
deviation and were compared using the Student’s
t-test. Categorical variables are expressed as counts
and percentages and were compared with the
chi-square or Fisher exact test, as appropriate. Pre-
dictors of NOAF in patients undergoing CABG were
determined in a Cox proportional hazards model
including the following clinical and angiographicvariables: age, sex, history of medically treated dia-
betes, history of hypertension, history of congestive
heart failure, recent MI (<7 days), body mass index
(BMI), baseline hemoglobin, baseline renal insufﬁ-
ciency (creatinine clearance <60 ml/min), left ven-
tricular ejection fraction (LVEF), angiographic core
laboratory–assessed SYNTAX score, off-pump versus
on-pump CABG, number of bypass conduits, and
bypass of the left circumﬂex artery. The same model
was tested in patients who underwent off-pump
surgery. A second Cox proportional hazards model
was constructed in patients who underwent on-
pump surgery including the foregoing covariates
(except off-pump vs. on-pump surgery) in addition
to bypass duration, cross-clamp duration, use of
crystalloid cardioplegia, and retrograde cardioplegia.
Event rates at 30 days and 3 years were estimated
using the Kaplan-Meier method, with comparisons
made using the log-rank test. Multivariable Cox
proportional hazard analyses were used to determine
whether NOAF was an independent predictor of
all-cause death, cardiovascular death, stroke, and the
primary composite outcome measure of death, MI, or
stroke at 3 years. The following covariates were
included in the model: NOAF, age, sex, medically
treated diabetes, history of hypertension, history of
congestive heart failure, recent MI (<7 days), BMI,
baseline renal insufﬁciency, LVEF, left main distal
bifurcation lesion, and core laboratory SYNTAX score.
Multivariable analyses were also performed in the
CABG cohort alone with the same variables, in addi-
tion to on-pump versus off-pump surgery. A 2-sided
p value <0.05 was considered to be statistically
signiﬁcant for all tests. All statistical analyses were
performed with SAS software, version 9.4 (SAS Insti-
tute, Cary, North Carolina).
RESULTS
BASELINE AND PROCEDURAL CHARACTERISTICS. Among
the 1,905 patients randomized in EXCEL, 70 had
in-hospital AF before revascularization, and 23 did
not undergo PCI or CABG. Thus 1,812 randomized
patients with LMCAD without AF on presentation
were included in the analysis, including 893 and 919
patients treated with CABG and PCI, respectively.
NOAF developed at a mean of 2.7  2.5 days after
revascularization in 162 patients (8.9%), including
161 of 893 (18.0%) CABG-treated patients and 1 of 919
(0.1%) PCI-treated patients (p < 0.0001). All NOAF
episodes consisted of AF; 1 patient had both AF and
atrial ﬂutter. Baseline characteristics of patients with
and without NOAF are shown in Table 1. Patients with
NOAF were older and were more likely to have a
TABLE 2 Procedural Characteristics According to the Development of In-Hospital
New-Onset Atrial Fibrillation
NOAF
(n ¼ 162)
No NOAF
(n ¼ 1,650) p Value
PCI group (including staged procedures)
Hemodynamic support device used 0/2 (0.0) 54/999 (5.4) 1.00
PCI of the distal left main bifurcation 1/1 (100.0) 516/908 (56.8) 1.00
Procedure duration, min 103.0  4.2 80.6  42.4 0.24
CABG group
Revascularization priority
Emergent 15/161 (9.3) 86/732 (11.7) 0.38
Urgent 55/161 (34.2) 235/732 (32.1) 0.61
Elective 91/161 (56.5) 411/732 (56.1) 0.93
Off-pump coronary artery bypass grafting 43/161 (26.7) 217/732 (29.6) 0.46
Intermittent cross-clamp 36/118 (30.5) 153/515 (29.7) 0.86
Crystalloid cardioplegia 25/118 (21.2) 158/513 (30.8) 0.04
Blood cardioplegia 89/118 (75.4) 332/513 (64.7) 0.03
Direction of cardioplegia
Antegrade 106/118 (89.8) 450/515 (87.4) 0.46
Retrograde 40/118 (33.9) 112/515 (21.7) 0.005
Other surgical procedures performed 106/118 (89.8) 450/515 (87.4) 0.46
Number of conduits per patient 2.6  0.8 2.6  0.8 0.71
Internal mammary artery used 157/161 (97.5) 721/728 (99.0) 0.12
Pan-arterial revascularization 41/161 (25.5) 180/732 (24.6) 0.82
Vessels bypassed per subject 2.3  0.5 2.2  0.6 1.00
Coronary artery bypassed
Left anterior descending 158/160 (98.8) 720/728 (98.9) 0.70
Left circumﬂex 149/160 (93.1) 636/728 (87.4) 0.04
Right 54/160 (33.8) 279/728 (38.3) 0.28
CABG duration, min 252.6  78.9 240.9  67.7 0.11
Bypass duration, min 86.3  45.4 82.7  44.7 0.23
Cross-clamp duration, min 56.9  28.5 54.7  27.2 0.66
Values are mean  SD or n/N (%).
CABG ¼ coronary artery bypass grafting; NOAF ¼ new-onset atrial ﬁbrillation or ﬂutter; PCI ¼ percutaneous
coronary intervention.
TABLE 3 Independent Predictors of In-Hospital New-Onset Atrial Fibrillation in Patients
Undergoing Coronary Artery Bypass Grafting
Adjusted Hazard Ratio
(95% Conﬁdence Interval) p Value
Age, per yr 1.05 (1.03-1.07) <0.0001
Male 1.31 (0.82-2.11) 0.26
Body mass index, per kg/m2 1.05 (1.01-1.09) 0.009
Diabetes mellitus, medically treated 0.71 (0.47-1.08) 0.11
Hypertension, medically treated 0.92 (0.61-1.39) 0.68
Congestive heart failure 0.58 (0.24-1.39) 0.20
SYNTAX score, per unit 1.01 (0.99-1.03) 0.30
Creatinine clearance <60 ml/min 1.09 (0.64-1.87) 0.74
Baseline hemoglobin, per g/dl 1.00 (0.88-1.14) 0.50
Recent myocardial infarction 1.12 (0.70-1.79) 0.63
Left ventricular ejection fraction, % 0.97 (0.96-0.99) 0.02
On-pump surgery 0.80 (0.54-1.20) 0.29
Total number of bypass conduits 0.89 (0.70-1.14) 0.36
Bypass of the left circumﬂex artery 1.67 (0.86-3.21) 0.13
Abbreviation as in Table 1.
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743history of anemia and MI and lower LVEF. Pre-
procedure laboratory values were similar between
groups except for a slightly higher brain natriuretic
peptide level in patients with versus without NOAF.
Procedural characteristics were also similar in
patients with versus without NOAF except for more
frequent blood cardioplegia, retrograde cardioplegia,
and grafting of the left circumﬂex artery during the
index CABG (Table 2). Pre-operative amiodarone in
the CABG group was administered to 3 of 160 (1.9%)
patients and 12 of 727 (1.7%) patients, respectively,
who had or did not have in-hospital post-CABG NOAF
(p ¼ 0.11).
By multivariable analysis, the independent pre-
dictors of NOAF in patients undergoing CABG were
older age, greater BMI, and reduced LVEF (Table 3).
The C-statistics for the relationships among age, BMI,
LVEF, and the subsequent development of NOAF
were 0.62, 0.53, and 0.55, respectively. In patients
undergoing off-pump CABG, age (hazard ratio [HR]:
1.05; 95% conﬁdence interval [CI]: 1.03 to 1.08;
p < 0.0001), BMI (HR: 1.06; 95% CI: 1.01 to 1.09;
p ¼ 0.03), and LVEF (HR: 0.98; 95% CI: 0.96 to 0.99;
p ¼ 0.03) were conﬁrmed as important predictors of
NOAF. In patients undergoing on-pump surgery, age
and retrograde cardioplegia independently predicted
NOAF (Online Table 1).
By the time of hospital discharge, NOAF had
resolved in 139 of 162 patients (85.8%), including 20
patients who underwent cardioversion. The duration
of hospitalization was signiﬁcantly longer in patients
with versus without NOAF (14.3  10.9 days vs.
8.3  7.5 days; p < 0.0001). Discharge medications
varied substantially according to the occurrence of
NOAF (Table 4). Patients with NOAF were more
frequently discharged with anticoagulant therapy
with either warfarin or a novel oral anticoagulant
agent, whereas dual antiplatelet therapy was more
commonly prescribed to patients without NOAF.
Aspirin was equally prescribed in both groups.
Antiarrhythmic medications and diuretics were also
more frequently used in patients with NOAF.
CLINICAL OUTCOMES. The development of in-hospital
NOAF was associated with increased unadjusted
30-day rates of major and minor bleeding, but not
with adverse cardiovascular events; after multivari-
able adjustment adjusted for differences in baseline
characteristics, the 30-day risk for the composite
outcome of death, MI, or stroke was higher in patients
with NOAF compared with patients without NOAF
(Online Table 2). At 3 years, in addition to major and
minor bleeding, NOAF was associated with increased
rates of all-cause death, cardiovascular death, stroke,
TABLE 4 Medications at Discharge According to the Development of In-Hospital
New-Onset Atrial Fibrillation
NOAF
(n ¼ 162)
No NOAF
(n ¼ 1,650) p Value
Aspirin 155/157 (98.7) 1,597/1,612 (99.1) 0.66
CABG group 154/156 (98.7) 711/717 (99.2) 0.59
PCI group 1/1 (100.0) 886/895 (99.0) 0.91
ADP antagonist 54/158 (34.2) 1,120/1,617 (69.3) <0.0001
CABG group 53/157 (33.8) 241/719 (33.5) 0.95
PCI group 1/1 (100.0) 879/898 (97.9) 0.16
Both aspirin and ADP antagonist 53/158 (33.5) 1,107/1,617 (68.5) <0.0001
CABG group 52/157 (33.1) 237/719 (33.0) 0.97
PCI group 1/1 (100.0) 870/898 (96.9) 0.16
Warfarin 16/158 (10.1) 19/1,617 (1.2) <0.0001
Novel oral anticoagulant agent 0/158 (0.0) 2/1,617 (0.1) 1.00
Warfarin or novel oral
anticoagulant agent
16/158 (10.1) 21/1,617 (1.3) <0.0001
CABG group 16/157 (10.2) 15/719 (2.1) <0.0001
PCI group 0/1 (0.0) 6/898 (0.7) 0.74
Low-molecular-weight heparin 3/158 (1.9) 10/1,617 (0.6) 0.10
CABG group 3/157 (1.9) 5/719 (0.7) 0.15
PCI group 0/1 (0.0) 5/898 (0.6) 0.94
Antiarrhythmic agent 72/158 (45.6) 34/1,617 (2.1) <0.0001
CABG group 72/157 (45.9) 30/719 (4.2) <0.0001
PCI group 0/1 (0.0) 4/898 (0.4) 0.95
Beta-blocker 144/158 (91.1) 1,412/1,617 (87.3) 0.16
CABG group 143/157 (91.1) 667/719 (92.8) 0.47
PCI group 1/1 (100.0) 745/898 (83.0) 0.65
Calcium channel blocker 16/158 (10.1) 99/1,617 (6.1) 0.051
CABG group 16/157 (10.2) 45/719 (6.3) 0.08
PCI group 0/1 (0.0) 54/898 (6.0) 0.80
ACE inhibitor or ARB 69/158 (43.7) 809/1,617 (50.0) 0.13
CABG group 69/157 (43.9) 300/719 (41.7) 0.61
PCI group 0/1 (0.0) 509/898 (56.7) 0.25
Statin 145/158 (91.8) 1,532/1,617 (94.7) 0.12
CABG group 144/157 (91.7) 666/719 (92.6) 0.70
PCI group 1/1 (100.0) 866/898 (96.4) 0.84
Diuretic 48/158 (30.4) 196/1,617 (12.1) <0.0001
CABG group 48/157 (30.6) 165/719 (22.9) 0.04
PCI group 0/1 (0.0) 31/898 (3.5) 0.85
Values are n/N (%).
ACE ¼ angiotensin-converting enzyme; ADP ¼ adenosine diphosphate receptor; ARB ¼ angiotensin receptor
blocker; other abbreviations as in Table 2.
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744and the primary composite endpoint of death, MI, or
stroke (Table 5). By multivariable analysis, NOAF was
an independent predictor of all-cause death, cardio-
vascular death, stroke, and the primary composite
outcome of all-cause death, MI, or stroke at 3 years in
the overall population and in the CABG-treated group
(Table 6).
The increased 3-year rate of cardiovascular death
in patients with versus without NOAF was driven by
deaths adjudicated as stroke related and heart failure
related (2.6% vs. 0.6%; p ¼ 0.005; and 1.9% vs. 0.4%;
p ¼ 0.009, respectively). Among the 10 patients with
in-hospital NOAF who had a stroke during follow-up,
5 (50%) were not taking warfarin or a novel oralanticoagulant agent at the time of the event. As
shown in the Central Illustration, the rate of the 3-year
composite primary endpoint of death, MI, or stroke
was reduced in patients treated with PCI compared
with patients treated with CABG who had NOAF
development. In contrast, PCI and CABG had
nonsigniﬁcantly different rates of the 3-year primary
endpoint if NOAF did not occur.
DISCUSSION
The major ﬁndings from the present analysis from the
EXCEL trial, in which the incidence, predictors, and
prognostic impact of in-hospital NOAF in patients
with LMCAD undergoing PCI or CABG were examined,
are as follows: 1) NOAF was frequent after CABG but
extremely rare after PCI; 2) older age, greater BMI,
and reduced LVEF were independent predictors of
NOAF after CABG; 3) NOAF was associated with pro-
longed hospitalization and increased 30-day rates of
bleeding; and 4) NOAF was a strong independent
predictor of the 3-year rates of all-cause and cardio-
vascular death, stroke, and the primary composite
endpoint of death, MI, or stroke after CABG.
Among patients with LMCAD and sinus rhythm
who were enrolled in the EXCEL trial, in-hospital
NOAF was much more likely to develop after CABG
than after PCI. The 18% rate of NOAF after CABG for
LMCAD in the present study is consistent with prior
reports in which post-CABG AF developed in 11% to
40% of patients (7–10). The range of post-operative
NOAF between studies likely reﬂects differences in
patient populations (e.g., operative urgency, critical
state, and hemodynamic stability), the use of pre-
operative prophylactic therapies (e.g., beta-blockers
and amiodarone), and variability in the rigor and
duration of detection. Patients enrolled in EXCEL
were relatively stable and not high risk, with equi-
poise for revascularization by either PCI or surgery.
Nonetheless, in-hospital NOAF occurred in only 1
patient after PCI, markedly less than after CABG, a
ﬁnding reﬂecting in part the fact that relatively few
patients in EXCEL presented with acute MI, a cohort
more commonly affected by post-PCI AF (11–13).
NOAF was a powerful predictor of adverse out-
comes during 3-year follow-up after CABG, in partic-
ular stroke, cardiovascular death, and all-cause
death. Notably, NOAF was a stronger multivariable
predictor of death after CABG than either diabetes or
reduced LVEF. As shown in the Central Illustration,
PCI had superior 3-year event-free survival compared
with CABG if NOAF after surgery occurred. PCI may
thus be preferred in selected patients who have a very
high risk of NOAF after surgery. In this regard,
TABLE 6 Independent Predictors of 3-Year Clinical Outcomes*
All Patients (n ¼ 1,812) CABG Group (n ¼ 893)
Hazard Ratio
(95% Conﬁdence Interval) p Value
Hazard Ratio
(95% Conﬁdence Interval) p Value
All-cause death
NOAF 2.06 (1.21-3.50) 0.008 3.02 (1.60-5.7) 0.0006
Age 1.03 (1.01-1.06) 0.02 — —
Left ventricular ejection fraction, % 0.97 (0.96-0.99) 0.008 0.97 (0.93-0.99) 0.03
Diabetes mellitus 1.77 (1.16-2.69) 0.008 — —
Congestive heart failure — — 2.48 (1.00-6.12) 0.049
Cardiovascular death
NOAF 3.25 (1.76-5.98) 0.0002 4.86 (2.27-10.44) <0.0001
Diabetes mellitus 1.92 (1.12-3.31) 0.02 — —
Left ventricular ejection fraction, % 0.97 (0.95-1.00) 0.048 — —
Stroke
NOAF 4.08 (1.89-8.78) 0.0003 4.19 (1.74-10.11) 0.001
Renal insufﬁciency 2.29 (1.02-5.13) 0.045 — —
Diabetes mellitus 2.52 (1.29-4.93) 0.007 3.22 (1.32-7.87) 0.01
Male 0.47 (0.24-0.92) 0.03 — —
Body mass index 0.91 (0.85-0.98) 0.01 — —
Composite death, MI, or stroke
NOAF 1.84 (1.26-2.68) 0.002 2.13 (1.39-3.25) 0.0004
Diabetes mellitus 1.55 (1.17-2.07) 0.003 1.63 (1.08-2.44) 0.02
Hypertension — — 1.68 (1.00-2.82) 0.048
Renal insufﬁciency 1.51 (1.04-2.19) 0.03 — —
*The full list of covariates tested appears in the Methods section. Covariates not appearing in the table were not statistically signiﬁcant in the ﬁnal models.
Abbreviations as in Tables 1 and 2.
TABLE 5 Clinical Outcomes at 3 Years According to the Development of In-Hospital New-Onset Atrial Fibrillation
All Patients CABG-Treated Patients
NOAF
(n ¼ 162)
No NOAF
(n ¼ 1,650) p Value
NOAF
(n ¼ 161)
No NOAF
(n ¼ 893) p Value
Death, MI, or stroke 19.3 (36) 12.8 (208) 0.02 22.6 (36) 12.8 (93) 0.002
All-cause death 11.3 (18) 6.1 (99) 0.01 11.4 (18) 4.3 (31) 0.0005
Cardiovascular 8.9 (14) 3.4 (55) 0.0007 9.0 (14) 2.4 (17) <0.0001
Noncardiovascular 2.6 (4) 2.8 (44) 0.94 2.6 (4) 2.0 (14) 0.61
MI 11.4 (18) 8.0 (130) 0.14 11.4 (18) 8.0 (58) 0.19
Stroke or TIA 7.9 (12) 2.8 (44) 0.0007 7.9 (12) 3.0 (21) 0.005
Stroke 6.5 (10) 2.3 (37) 0.002 6.6 (10) 2.4 (17) 0.009
Ischemic 5.3 (8) 1.8 (28) 0.004 5.4 (8) 2.1 (15) 0.03
Hemorrhagic 1.3 (2) 0.7 (11) 0.40 1.3 (2) 0.4 (3) 0.20
TIA 1.4 (2) 0.4 (7) 0.14 1.4 (2) 0.6 (4) 0.31
Bleeding
TIMI major/minor 16.8 (27) 6.7 (109) <0.0001 16.9 (27) 8.6 (63) 0.002
TIMI major 6.8 (11) 2.8 (46) 0.005 6.9 (11) 4.0 (29) 0.11
TIMI minor 10.6 (17) 3.9 (64) <0.0001 10.7 (17) 4.7 (34) 0.004
BARC scale, any 18.6 (30) 12.9 (210) 0.03 18.8 (30) 15.4 (112) 0.29
Type 1 0.0 (0) 2.4 (39) 0.05 0.0 (0) 2.1 (15) 0.07
Type 2 6.9 (11) 5.5 (89) 0.44 6.9 (11) 5.0 (36) 0.32
Type 3 8.7 (14) 4.1 (67) 0.007 8.8 (14) 5.2 (38) 0.09
Type 4 7.5 (12) 2.9 (47) 0.002 4.4 (7) 3.3 (24) 0.49
Type 5 4.3 (7) 1.5 (25) 0.009 0.0 (0) 0.1 (1) 0.64
Values are Kaplan-Meier estimates, presented as % (n).
BARC ¼ Bleeding Academic Research Consortium; CI ¼ conﬁdence interval; HR ¼ hazard ratio; MI ¼ myocardial infarction; TIA ¼ transient ischemic attack,
TIMI ¼ Thrombolysis in Myocardial Infarction; other abbreviations as in Tables 1 and 2.
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CENTRAL ILLUSTRATION Atrial Fibrillation After Left Main Revascularization
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CABG-NOAF vs PCI, HR: 1.61 [95% CI: 1.11-2.32], P = 0.01
CABG-NOAF vs CABG–no NOAF, HR: 1.80 [95% CI: 1.22-2.64], P = 0.002
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Kosmidou, I. et al. J Am Coll Cardiol. 2018;71(7):739–48.
Time-to-event curves and adjusted hazard ratios (HR) for the 3-year primary composite endpoint of death, myocardial infarction (MI), or stroke in patients with left
main coronary artery disease without pre-procedural atrial ﬁbrillation who underwent revascularization by percutaneous coronary intervention (PCI) (n ¼ 919) versus
coronary artery bypass grafting (CABG) with the subsequent development of new-onset atrial ﬁbrillation (NOAF) before hospital discharge (n ¼ 161) versus coronary
artery bypass grafting without new-onset atrial ﬁbrillation before hospital discharge (n ¼ 732). The 3-year adverse event rates were highest in coronary artery bypass
grafting–treated patients with new-onset atrial ﬁbrillation and similar in coronary artery bypass grafting–treated patients without new-onset atrial ﬁbrillation and in
percutaneous coronary intervention–treated patients. CI ¼ conﬁdence interval.
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746advanced age, increased BMI, and reduced LVEF were
independent clinical predictors of NOAF after CABG
for LMCAD, consistent with previous reports (7,14,15).
However, although these associations were statisti-
cally signiﬁcant, the C-statistics for the correlations
between these risk factors and NOAF were modest,
and many patients who may beneﬁt from CABG
have these characteristics (16). Thus, although the
increased periprocedural risk of NOAF should be
recognized in patients with advanced age, increased
BMI, and/or reduced LVEF, rather than avoiding
CABG in these patients, effective pre-operative and
perioperative measures (prophylactic beta-blockers
or amiodarone) (17,18) should be considered to pre-
vent the post-surgical occurrence of NOAF. Consis-
tent with previous reports (19,20), the strategy of
surgical revascularization (on-pump vs. off-pump) in
EXCEL was not a predictor of NOAF.
In patients undergoing on-pump CABG, the use of
retrograde cardioplegia was a strong predictor of
NOAF. Potential adverse effects of retrograde car-
dioplegia have been previously reported (21), and
they may in part be related to the delay in cardiac
arrest and subsequent myocardial protection with
retrograde compared with antegrade cardioplegia.However, total bypass duration and cross-clamp
duration were not associated with an increased risk
for AF, a ﬁnding suggesting that alternate mecha-
nisms may underlie the increased rate of NOAF with
retrograde cardioplegia.
The higher periprocedural rates of stroke with
CABG compared with PCI that has been noted in most
prior trials (22,23) may in part be explained by the
greater rate of NOAF after surgical revascularization
(24). Although a recent large registry-based analysis
suggested that post-operative AF was a predictor only
of early stroke (25), in the present study the increased
rate of stroke with in-hospital NOAF emerged not
within 30 days, but during long-term follow-up. A low
proportion (10.2%) of patients with NOAF after CABG
in EXCEL was discharged with long-term oral anti-
coagulant therapy (reﬂecting the high in-hospital rate
of conversion to sinus rhythm), and although the
3-year post-CABG rate of stroke was relatively low
compared with prior studies, 50% of the post-CABG
NOAF patients who developed a stroke during
follow-up were not being treated with anticoagulant
therapy at the time. Future studies are warranted to
determine the extent to which recurrent AF during
long-term follow-up contributed to the late stroke
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: AF occurs much more commonly after CABG surgery
than after PCI. Patients developing AF after CABG for LMCAD
face elevated risks of stroke, cardiovascular mortality, and all-
cause mortality during the subsequent 3 years than do patients
without AF.
TRANSLATIONAL OUTLOOK: Additional studies are needed
to determine whether long-term monitoring for detection of AF
after CABG and oral anticoagulant therapy could improve the
prognosis of patients undergoing CABG for LMCAD.
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747risk (26,27). Alternatively, in-hospital NOAF that
resolves may be a marker of high-risk patients’
characteristics, systemic inﬂammation, and diffuse
vascular atherosclerosis (28), thus predisposing
patients with NOAF to thrombotic or atheroembolic
events (29), with or without recurrent AF. Continuous
monitoring may elucidate whether recurrent AF epi-
sodes precede cerebrovascular events in this patient
population.
In addition to affecting long-term prognosis, NOAF
was strongly associated with prolonged hospitaliza-
tion, likely attributable to its management (rate
control and attempted pharmacological or electrical
cardioversion, diuresis, and initiation of anti-
coagulation in some patients), and with bleeding
complications (in part from anticoagulation) that may
have contributed to the poor prognosis of patients
with NOAF (30,31). The ongoing formal EXCEL cost
substudy will assess the extent to which NOAF
increased costs in CABG-treated patients.
STUDY STRENGTHS AND LIMITATIONS. As a large
randomized trial of patients with LMCAD who were
undergoing revascularization, EXCEL provides
clinically relevant insights regarding the relative
frequency of NOAF after PCI and CABG and of its
association with long-term cardiovascular outcomes.
However, several limitations should be considered.
First, the present analysis was post hoc, and it should
thus be considered hypothesis generating. Second,
the absolute number of events (NOAF, stroke, and
death) was modest, and not all confounders in their
described relationships may have been identiﬁed.
Third, although we excluded patients with
in-hospital AF before revascularization from the
present analysis, a history of prior AF was not
captured in the case report form and systematic
screening for pre-operative AF was not done; as such,
pre-procedure episodes of AF may have been missed.
Fourth, pre-CABG use of amiodarone was uncommon,
and data on the rate of perioperative beta-blocker
use were not collected. We thus cannot speak to the
efﬁcacy of these measures in preventing NOAF orinﬂuencing prognosis. Finally, data on arrhythmias
during follow-up (including AF recurrence) were not
systematically collected in the present study.
CONCLUSIONS
In the randomized EXCEL trial comparing PCI and
CABG for the treatment of LMCAD in patients with low
and intermediate SYNTAX scores, NOAF occurred
almost exclusively following CABG andwas a powerful
predictor of all-cause death, cardiovascular death,
stroke, and the composite endpoint of death, MI, or
stroke at 3 years. Further studies are needed to iden-
tify patients at high risk for NOAF after CABG to guide
prophylactic measures, to examine the potential role
of implantable monitors to detect AF recurrence in
patients with NOAF who convert to sinus rhythm
before hospital discharge, and to determine whether
the routine use of long-term oral anticoagulation in
patients with in-hospital NOAF improves long-term
prognosis after CABG for LMCAD.
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